Mark A. Goldsmith, an insider at Revolution Medicines Inc (RVMD), purchased 307,863 shares on November 24, 2025, at a price of $4.09 per share, totaling $1.26 million. Following this transaction, Goldsmith holds 307,863 shares of the biotechnology company.
Revolution Medicines, based in Redwood City, California, specializes in developing novel targeted therapies in precision oncology. The company is currently advancing its RAS(ON) inhibitors, which are in clinical development and target specific RAS variants. Revolution Medicines has a market cap of $15.0 billion and reported a trailing twelve-month EPS of -2.73.
Insider buying can indicate confidence in a company's prospects, as executives typically have access to non-public information. However, investors should consider insider transactions as one of many factors when evaluating potential investments.
The company is set to announce its upcoming earnings on May 5, 2026, with an estimated EPS of -1.69, and again on August 4, 2026, with an estimated EPS of -1.76.
Investors are encouraged to examine broader patterns of insider activity rather than isolated transactions to gain a clearer perspective on executive sentiment.